| Martha Alicia Chavez-rangel, FNP | |
|
1401 W 1st St Ste 101, Santa Ana, CA 92703-3757 | |
| (714) 542-9700 | |
| (714) 542-9708 |
| Full Name | Martha Alicia Chavez-rangel |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 1401 W 1st St Ste 101, Santa Ana, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073384608 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 95027488 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Martha Alicia Chavez-rangel, FNP 510 S Alvarado St, Los Angeles, CA 90057-2904 Ph: (213) 483-3600 | Martha Alicia Chavez-rangel, FNP 1401 W 1st St Ste 101, Santa Ana, CA 92703-3757 Ph: (714) 542-9700 |
News Archive
Just as the repeal positions of some big insurers are becoming more clear, more details on the Democrats' strategy to defend the law are emerging.
If the obvious reasons for avoiding recreational drug use aren't off-putting enough, physicians have yet another detrimental consequence to add to the list - crusty, purplish areas of dead skin that are extremely painful and can open the door to nasty infections.
Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).
Conclusive data show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA) and reduces the risk of stroke, prompting early termination by the National Heart Lung and Blood Institute of a key clinical trial studying the drug's efficacy.
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
› Verified 7 days ago
Mr. Gerardo M De Jesus, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 550 N Flower St, Santa Ana, CA 92703 Phone: 714-647-4170 | |
Miss Sonia Sedano, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1400 N Main St, Santa Ana, CA 92701 Phone: 888-499-9303 | |
Melissa A Medellin, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1002 N Fairview St, Santa Ana, CA 92703 Phone: 714-835-8501 | |
Elizabeth Branson, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2010 E 1st St # 100, Santa Ana, CA 92705 Phone: 909-800-3532 | |
Mr. Ramoncito Llorin Cimarra, PMHNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2001 E 4th St Ste 200, Santa Ana, CA 92705 Phone: 562-735-9541 | |
Kimberly A Umansky, NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1751 E Garry Ave, Santa Ana, CA 92705 Phone: 877-896-7350 | |
Yingxuan Law, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1801 Park Court Pl Bldg H, Santa Ana, CA 92701 Phone: 206-817-2984 |